The Bothell Cascade Business Park hosts the world’s headquarters of Seattle Genetics. The environment seems unfamiliar with a scientific venture but becomes clearer when one nears the lobby of building three. In place is a green triangular sculpture made of Lego bricks forming a simple model of a human antibody. Seattle Genetics has dedicated its entire study to human antibodies and has put into place techniques to study, manipulate, and package them into drugs. The organization was founded in 1997 and is based on the grounds of catapulting their findings into the big leagues.
The human antibody has been used to form a connection in the form of therapy giving it the ability to offload a toxic payload into the vicinity of a cancer cell thus destroying it from within. It is a hope that Seattle’s biotech community pushes through with this incumbent innovation despite the many hurdles in the sector. The company has a market value of about $10 billion and boasts of a wide personnel team with over 900 employees making it the largest biotech all over Washington.
The company is determined to move from being a biotech into a big pharmaceutical. A great investment is put in research and marketing with an expectation of increasing its number of employees by 200 before the year ends. Clay Siegall, the company’s CEO, declares that they are now emerging globally, standing as a multiproduct oncology organization. He says that the company has the desire to go big and is currently running with a long list of drugs on their pipeline.
About Clay Siegall
Dr. Clay Siegall is among the founders of the Seattle Genetics, which was initiated in 1998. He also holds the position of CEO, President, and is part of its Board of Directors. He holds a B.S in Zoology from the University of Maryland and earned a Ph.D. in Genetics from the George Washington University. During his service at Seattle Genetics, the company has achieved the innovation and implementation of antibody-based cancer therapies. Among the therapies introduced include the ADCETRIS (brentuximab vedotin) which got its approval from the U.S. Food and Drug Administration in 2011. Dr. Clay has also chaperoned other activities in Seattle Genetics with regards to capital rising. Collectively, they have secured up to $675 million through both private and public funding.
Prior to his leadership and service at Seattle Genetics, Siegall worked for six years at the Bristol-Myers Squibb Pharmaceutical Research Institute and at the National Cancer Institute, National Institute of Health for three years. Dr. Clay is part of a private biotechnology company, the Alder BioPharmaceuticals where he is a member of the Board of Directors. He has his own publishing which includes over 70 publications and still holds 15 patents.